Cover Image

Asymptomatic SARS-CoV2 infection in a patient receiving risankizumab, an inhibitor of interleukin 23

Saved in:

Bibliographic Details
Main Authors:	Madison Ward, BSc, MD (Author), Melinda Gooderham, MD, MSc, FRCPC (Author)
Format:	Book
Published:	Elsevier, 2021-01-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Efficacy and safety of treatment of moderate and severe psoriasis with the interleukin 23 inhibitor risankizumab
by: Andrey L. Bakulev, et al.
Published: (2022)

Real-world effectiveness and safety of risankizumab in patients with plaque psoriasis in whom guselkumab failed recently: A multicenter retrospective study of switching within the interleukin-23 inhibitor class
by: Ahmed Bagit, BSc, et al.
Published: (2023)

Use of risankizumab in two HIV-positive patients with psoriasis
by: Khalad Maliyar, MD, BA, et al.
Published: (2023)

Interleukin-23 Inhibitors
by: Esra Adışen
Published: (2022)

New-onset systemic lupus erythematous in a patient receiving risankizumab for psoriasis
by: Cara Barber, MD, MPH, et al.
Published: (2022)

Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis
by: Haugh IM, et al.
Published: (2018)

The role of interleukin-17 and interleukin-23 inhibitors in the development, progression, and recurrence of cancer: A systematic reviewCapsule Summary
by: Marie Vangilbergen, MD, et al.
Published: (2024)

Speed and Cumulative Responses According to Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Ixekizumab (Interleukin-17A Antagonist) versus Guselkumab (Interleukin-23p19 Inhibitor)
by: Melinda Gooderham, et al.
Published: (2024)

Acquired perforating dermatosis associated with risankizumab
by: Munira Alhadlg, MD, et al.
Published: (2024)

Delayed Kawasaki disease in an adult previously infected with SARS-CoV-2
by: Sheila Wang, MD, PhD, et al.
Published: (2022)

Targeting Interleukin 13 for the Treatment of Atopic Dermatitis
by: Yuliya Lytvyn, et al.
Published: (2023)

Risankizumab-associated lichen planus pemphigoides
by: Jessica Sparks, et al.
Published: (2023)

Oocyte Retrieval in Asymptomatic Patients Positive for SARS-CoV-2
by: Allison Akers, et al.
Published: (2022)

The challenge of asymptomatic SARS-CoV-2 transmission in care homes
by: Joël Belmin, et al.
Published: (2021)

Clinical Features of Asymptomatic SARS-CoV-2 Infection in Hemodialysis Patients
by: Maria Soledad Pizarro-Sánchez, et al.
Published: (2021)

Risankizumab for the treatment of pityriasis rubra pilaris postanaplastic large cell lymphoma
by: Georgia Koroneos, BSc, MD, et al.
Published: (2024)

Dermatology: how to manage acne in skin of colour
by: Claire Chiang, et al.
Published: (2022)

Review of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasis
by: Nora Koutruba, et al.
Published: (2010)

Inflammatory bowel disease in patients with psoriasis treated with interleukin-17 inhibitors
by: Keira A Fieldhouse, et al.
Published: (2020)

Asymptomatic SARS-CoV-2 Carriers: A Systematic Review and Meta-Analysis
by: Gopiram Syangtan, et al.
Published: (2021)

Do asymptomatic carriers of SARS-COV-2 transmit the virus?
by: Claude P. Muller
Published: (2021)

A Review of Interleukin-23/Interleukin-17 Inhibitor Exposure during Pregnancy in Patients with Psoriasis
by: Nirali Doshi, et al.
Published: (2024)

Rapid and sustained remission of synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome with IL-23p19 antagonist (risankizumab)
by: Akshay Flora, MD, MMed, et al.
Published: (2021)

Correlations of interleukin levels with the severity of SARS-CoV-2 coronavirus infection
by: O. N. Yashkina, et al.
Published: (2023)

Interleukin-6 levels in children developing SARS-CoV-2 infection
by: Gita Vita Soraya, et al.
Published: (2020)

The use of interleukin 23 inhibitors in patients with chronic hepatitis B infection: A case series
by: Peter Yi Ch'en, BS, et al.
Published: (2022)

The coverage of SARS-CoV-2 vaccination and the willingness to receive the SARS-CoV-2 variant vaccine among employees in China
by: Xi-Ru Zhang, et al.
Published: (2023)

A SARS-CoV-2 familial cluster infection reveals asymptomatic transmission to children
by: Ming Chen, et al.
Published: (2020)

Molecular detection of SARS-CoV-2 being challenged by virus variation and asymptomatic infection
by: Congshan Jiang, et al.
Published: (2021)

Reported Case of Asymptomatic SARS-CoV-2-carriage in the Child with Severe Chronic Disease
by: Irina I. Spichak, et al.
Published: (2020)

SARS-CoV-2 Serology Testing in an Asymptomatic, At-Risk Population: Methods, Results, Pitfalls
by: Theodore Heyming, et al.
Published: (2021)

Mycosis fungoides diagnosed after exposure to risankizumab for psoriasis
by: Lauren M. Fahmy, BS, et al.
Published: (2023)

Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort study
by: Yuliya Lytvyn, PhD, et al.
Published: (2022)

Reverse koebnerization of primary cutaneous follicle center lymphoma following skin biopsy
by: Bohmyi Choi, BSc, et al.
Published: (2021)

Nucleotide analogues as inhibitors of SARS‐CoV Polymerase
by: Jingyue Ju, et al.
Published: (2020)

Coronaviruses SARS-CoV, MERS-CoV, and SARS-CoV-2 helicase inhibitors: a systematic review of in vitro studies
by: Nimer Mehyar
Published: (2023)

Clinical efficacy of risankizumab in patients with psoriasis: A Japanese case series
by: Kanako Tsunoda, MD, PhD, et al.
Published: (2024)

Prevalence of Co-Infections and Pathogens in Hospitalized Children with Acute Respiratory Infections: A Comparative Analysis Between SARS-CoV-2 and Non-SARS-CoV-2 Cases
by: Visal Moolasart MD, et al.
Published: (2024)

SARS-CoV-2 induced IgA vasculitis confirmed with SARS-CoV-2 tissue testing
by: Ahmed N. Ansari, MD, et al.
Published: (2024)

Long-term asymptomatic SARS-CoV-2 infection associated with deficiency on multiple immune cells
by: Gang He, et al.
Published: (2022)